Income Statement
TRAVERE THERAPEUTICS, INC.
TVTX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY | Dec 31, 2012 2012 FY | Feb 29, 2012 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
490.73 | 233.18 | 145.24 | 212.02 | 227.49 | 198.32 | 175.34 | 164.25 | - | - | - | - | - | - | 0.00 |
|
Cost of Revenue
|
10.34 | 7.74 | 11.45 | 7.59 | 6.78 | 6.13 | 5.23 | 5.53 | - | - | - | - | - | - | - |
|
Gross Profit
|
480.39 | 225.43 | 133.79 | 204.43 | 220.71 | 192.20 | 170.10 | 158.72 | - | - | - | - | - | - | - |
|
Operating Expenses
|
337.20 | 264.12 | 265.54 | 220.21 | 149.88 | 135.80 | 269.91 | 244.29 | 208.73 | 191.81 | 150.64 | 108.01 | 23.97 | 30.26 | 0.01 |
|
Research & Development
|
206.01 | 217.50 | 244.99 | 235.78 | 210.33 | 131.77 | 140.96 | 123.76 | 78.17 | 70.85 | 50.43 | 47.80 | 7.08 | - | - |
|
Selling, General & Administrative
|
337.20 | 264.12 | 265.54 | 220.21 | 149.88 | 135.80 | 128.95 | 103.65 | 101.33 | 92.80 | 79.54 | 59.64 | 16.89 | 1.29 | 0.01 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
143.19 | -38.69 | -131.75 | -15.78 | 70.82 | 56.40 | -99.81 | -85.57 | -208.73 | -191.81 | -150.64 | -108.01 | -23.97 | -30.26 | -0.01 |
|
Non-Operating Income
|
13.55 | 3.32 | 12.03 | -11.60 | -17.92 | -12.63 | -9.09 | -21.83 | -4.57 | 0.63 | 156.22 | 5.39 | 9.78 | - | - |
|
Interest Income
|
12.72 | 17.82 | 21.77 | 6.28 | 1.99 | 5.00 | 10.06 | - | - | - | - | - | - | - | - |
|
Interest Expense
|
9.98 | 10.56 | 11.30 | 11.30 | 20.10 | 19.10 | 18.83 | 9.81 | 1.20 | 0.80 | 7.70 | 7.43 | -0.05 | 0.11 | - |
|
Other Non-Op Income / Expense
|
11.58 | -3.32 | 1.59 | 0.97 | 0.23 | 1.42 | -0.31 | -0.47 | 1.11 | -0.26 | -0.30 | -33.59 | - | - | - |
|
Income Before Tax
|
-2.71 | -152.36 | -82.83 | -62.27 | -55.55 | -65.88 | -17.00 | -14.29 | -2.75 | -4.83 | 107.04 | -113.40 | -33.75 | - | - |
|
Income Tax Expense
|
-23.73 | 1.04 | -264.71 | 0.31 | 0.41 | -19.36 | -0.02 | 0.81 | 1.37 | -9.68 | -10.20 | -2.46 | 0.08 | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Net Income
|
-25.55 | -321.55 | -111.40 | -278.48 | -180.09 | -169.43 | -146.43 | -102.68 | -59.73 | -47.90 | 117.24 | -110.94 | -33.82 | -30.34 | -0.01 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY | Dec 31, 2012 2012 FY | Feb 29, 2012 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
203.93 | 4.87 | -93.22 | 17.30 | 97.44 | 80.98 | -79.40 | -66.90 | -190.92 | -175.67 | -137.25 | -102.61 | -23.76 | -30.13 | -0.01 |
|
Earnings Per Share (Basic)
|
-0.29 | -4.08 | -1.50 | -4.37 | -3.01 | - | - | -2.54 | -1.54 | -1.29 | 3.49 | - | - | - | - |
|
Diluted EPS
|
-0.29 | -4.08 | -1.50 | -4.37 | -3.01 | - | - | -2.54 | -1.54 | -1.29 | 3.17 | - | - | - | - |
|
Weighted Average Shares
|
89.21 | 78.89 | 74.27 | 63.76 | 59.83 | - | - | 40.43 | 38.77 | 37.00 | 33.56 | - | - | - | - |
|
Diluted Weighted Avg Shares
|
89.21 | 78.89 | 74.27 | 63.76 | 59.83 | - | - | 40.43 | 38.77 | 38.29 | 37.58 | - | - | - | - |
|
Comprehensive Income
|
-26.66 | -320.17 | -109.95 | -280.83 | -179.75 | -171.06 | -144.17 | -103.19 | -60.26 | -47.71 | 112.27 | -106.54 | -33.93 | - | - |